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Liposomal bupivacaine (Exparel®) is a novel formulation of local anesthetic used to provide extended
postoperative analgesia as part of a multimodal pain control regimen in patients undergoing total joint
arthroplasty. In the three total hip arthroplasty cases described, all patients exhibited a transient loss of
neurologic function in the sciatic nerve distribution of the operated extremity lasting between 24 and
72 h during the immediate postoperative period. Due to the nature and duration of the deﬁcits, it was
concluded that they likely occurred as a result of unintended injection of the medication in close
proximity to the sciatic nerve. To the best of our knowledge, these events have yet to be reported in the
current literature. We recommend orthopaedic surgeons pay special attention during inﬁltration of the
medication at the surgical site to avoid postoperative neurological deﬁcits.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Pain control after total hip and total knee arthroplasty is a major
concern for both orthopaedic surgeons and their patients. Patient
perceptions of success or failure are related to pain relief and speed
of recovery [1]. Additionally, adequate pain control is associated
with early ambulation and return of normal gait kinematics [2,3].
In recent years, there has been a shift towards multimodal pain
control in total joint arthroplasty (TJA), which can include a pre-
operative, preemptive pharmacologic cocktail, intraoperative per-
iarticular injections, as well as a postoperative pharmacologic pain
protocol [4e6]. These protocols, which deemphasize high-dose
opiate use, have been shown to be effective in reducing opiate
use, improving pain scores, and permitting early ambulation. Un-
fortunately, the duration of action of commonly used periarticularclosed potential or pertinent
ent, either direct or indirect,
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rest with this work. For full
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c. on behalf of American Associatio
d/4.0/).injections is short, with bupivacaine or ropivacaine lasting only
8e12 h [7].
As an adjunct to these multimodal pain protocols, the use of
liposomal bupivacaine has recently gained popularity, offering the
pain relief of local bupivacaine with a longer analgesic effect.
Liposome-encapsulated bupivacaine (Exparel®, Pacira Pharmaceu-
ticals, Inc., San Diego, CA) gained FDA approval in October 2011. This
Depo-Foam bupivacaine consists of spherical, lipid-based particles
with encapsulated bupivacaine, allowing diffusion over an
extended period of time [8,9]. It has been shown to have bimodal
plasma concentration time, with an initial peak at approximately
1 h and a second peak between 12 and 24 h [8]. This formulation is
designed for a single-dose injection into the surgical site with
analgesia lasting up to 72 h [10]. Liposomal bupivacaine efﬁcacy is
highly technique dependent.
A systematic review analyzed the side effect proﬁle and safety of
Exparel in the published literature [11]. The most common side
effects were GI disturbances, fevers, and local site irritations.
Overall, however, the medication was well tolerated, with side
effects occurring within lower or equal rates as bupivacaine HCl.
Here we report on 3 cases of unintended postoperative sciatic
nerve deﬁcits following local injection of liposomal bupivacaine
during total hip arthroplasty. To our knowledge, these are the ﬁrst
cases reported in the literature.n of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
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Exparel® injection protocol
At our institution, the protocol for Exparel use in unilateral total
hip arthroplasty (THA) cases is as follows: 20 cc of Exparel (13.3mg/
ml) is combinedwith 40 cc of injectable 0.9% normal saline solution
(for a total solution amount of 60 cc) and is divided equally into
three 20 cc syringes. Before implanting the hip prosthesis, while the
entire joint is exposed, 20 cc is injected into the pericapsular tissue
(syringe #1), then 20 cc is injected in the fascia/muscle overlying
the joint (syringe #2), and the last 20 cc dose is injected into sub-
cuticular tissue beneath the incision (syringe #3).
Additionally, a periarticular injection consisting of 15 mg of
ketorolac, 5 mg of Duramorph, and 40 cc of 0.25% Marcaine is
inﬁltrated during closure of the incision (Marcaine is substituted for
ropivacaine to prevent Exparel breakdown). Patient controlled
analgesia (PCA), as well as preoperative and postoperative pre-
emptive oral analgesics (celecoxib, acetaminophen, and pre-
gabalin), are also given to THA patients.
Case 1
The patient is a 77 year-old female with a history of hyperten-
sion, hyperlipidemia, osteoarthritis, and past surgical history of
laminectomy L2-L5 and posterior spinal fusion T3-S1 for degener-
ative scoliosis and spinal stenosis 1 year prior. She complained of
pain in her right groin, buttock, and lateral thigh. She reported that
the right groin painwas not relieved by the recent spine procedure,
and had been getting progressively worse. Her right hip osteoar-
thritis was unresponsive to conservative measures. She had no
preexisting sensory or motor deﬁcits in her operative extremity due
to her spine issue and was neurovascularly intact preoperatively.
She underwent right total hip replacement via a posterior
approach under general anesthesia. For surgical infection prophy-
laxis, she received 2 g of aztreonam IVPB every 8 h over the course
of 24 h (6 g total), as well as 2 g of cefazolin IVPB every 8 h over the
course of 24 h (6 g total) starting at the time of surgery. The pro-
cedure was performed without any apparent deviations from
routine hip arthroplasty protocol. Exparel was inﬁltrated following
the described protocol. The operative leg was appropriately
lengthened 5 mm.
Postoperative neurologic motor exam in the recovery room after
regional anesthesia had resolved revealed 0/5 ankle dorsiﬂexion, 1/5
extensor hallucis longus, and 1/5 ankle plantar ﬂexion. Sensory exam
revealed absent sensation in common peroneal and tibial nerve
distributions. The patient did not complain of any pain or discomfort.
At this time a pillowwas placed underneath the knee to take tension
off of the sciatic nerve by ﬂexing the knee. The patient received a
morphine PCA (100 mg/100 mL) in the recovery room for overnight
pain control, which was discontinued in the morning of post-
operative day (POD) 1. For the remainder of her hospital stay, shewas
continued on an oral pain control regimen of acetaminophen 500mg
every 6 h, celecoxib 100 mg daily, pregabalin 50 mg twice daily, and
oxycodone IR 5 mg every 4 h as needed for breakthrough pain. Her
postoperative weight bearing status was weight bearing as tolerated
(WBAT) with awalker. By POD 2, ankle dorsiﬂexion improved to 2/5,
with extensor hallucis longus 4/5, and ankle plantar ﬂexion 4/5. An
ankle-foot orthosis was ordered for a suspected peroneal palsy after
THA; however she declined to wear it.
The patient progressed with physical therapy. On POD 3,
neurologic exam returned to normal with 5/5 strength and normal
sensation throughout all distributions. After the patient was able to
ambulate 150 feet with a wheeled walker and clear 8 stairs during
her POD 3 physical therapy session, she was discharged home (ourinstitutional mean length of stay for THA in 2014 was approxi-
mately 2.8 days). She received visiting nurse services for wound
care and physical therapy. She was instructed to continue WBAT,
administer enoxaparin (40 mg/0.4 ml) 0.4 ml subcutaneous in-
jections for venous thromboembolism prophylaxis for 4 weeks, and
take tramadol 50 mg every 4 h as needed for pain control. She had
an otherwise unremarkable postoperative course and had no
complaints or lower extremity neurological deﬁcits at her 1 and 3
month postoperative evaluations.
Case 2
The patient is a 38 year-old female with a history of asthma,
obesity (BMI 34.3), and developmental dysplasia of the hip who
developed early arthritis in her right hip. She complained of severe
pain in the right groin and buttock regions, no longer manageable
with non-operative measures. She is former smoker of 5 pack years
with a quit date 1 month prior to surgery. Preoperatively on
physical exam, she was neurovascularly intact. The patient had a
limb length discrepancy of 5 mm in the operative leg. She under-
went a right total hip arthroplasty via a posterior approach with
spinal anesthesia using 3 cc of 0.5% bupivacaine. For surgical
infection prophylaxis, she received a one-time intravenous dose of
gentamicin 360 mg, as well as 2 g of cefazolin IVPB every 8 h over
the course of 24 h (6 g total) starting at the time of surgery. The
procedure was performed without any apparent deviations from
routine hip arthroplasty protocol. Exparel was inﬁltrated into the 3
tissue locations according to the protocol. Postoperatively, leg
length measurements were restored to equal after lengthening the
operative extremity by 5 mm.
In the recovery room, she exhibited full strength in her tibialis
anterior, extensor hallucis longus, and gastrocnemius/soleus mus-
cle groups in her right leg. She reported a pain level of 8/10, which
was managed with a morphine PCA (100 mg/100 mL) in the re-
covery room and overnight after transfer to the ﬂoor. The PCA was
discontinued on the morning of POD 1. For the remainder of her
hospital stay, she was continued on an oral pain control regimen of
celecoxib 100mg daily, pregabalin 50mg twice daily, oxycodone CR
10 mg twice daily, and oxycodone IR 10 mg every 4 h as needed for
breakthrough pain.
By the end of POD 0, the patient was unable to ﬁre either tibialis
anterior or extensor hallucis and had decreased sensation in the
superﬁcial and deep peroneal nerve distributions on the right side.
The neurologic exam remained unchanged the morning of POD 1.
She was monitored closely with serial exams throughout POD 1
which demonstrated a progressive, restoration in function. By POD 2,
the patient was neurologically intact with 5/5 strength and normal
sensation in all distributions. The patient was made weight bearing
as tolerated with crutches and was able to meet established physical
therapy goals by walking 350 feet and clearing 4 stairs. At the end of
POD 2, she was discharged home. She received visiting nurse ser-
vices for wound care and physical therapy, was instructed to
continue WBAT, administer enoxaparin (40 mg/0.4 ml) 0.4 ml sub-
cutaneous injections for venous thromboembolism prophylaxis for 4
weeks, and take oxycodone-acetaminophen 5e325 mg as needed
for pain control. She had an otherwise unremarkable postoperative
course, and had no complaints or lower extremity neurological
deﬁcits at her 1 and 3 month postoperative evaluations.
Case 3
The patient is a 54 year-old male with a past medical history
signiﬁcant for frequent respiratory infections, presenting status-
post complicated left THA. His index THA was in 2008 for osteo-
arthritis and was a metal on metal bearing. In 2012, he underwent
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was successfully treated for the left hip periprosthetic joint infec-
tion (PJI) (group B streptococcus) with a two-stage resection and re-
implantation. In late 2014, he developed another PJI with a different
organism (group G streptococcus). The planwas to again treat with
a two-stage resection and re-implantation. He is presenting for the
second stage of his revision procedure with planned removal of the
antibiotic spacer and re-implantation of a left THA. Preoperatively,
he complained of severe pain in the left groin and had been using
crutches to ambulate on the unipolar antibiotic spacer. On physical
exam, he was neurovascularly intact.
He underwent left revision THA via a posterior approach with
general anesthesia. For surgical infection prophylaxis, he received
2 g of cefazolin IV, as well as 2 g of aztreonam IVPB every 8 h over
the course of 24 h (6 g total) starting at the time of surgery. A dilute
betadynewash was performed and 2 g of vancomycin powder were
added to the surgical wound prior to closure. Hewas also continued
on ceftriaxone 1 g IVPB during his hospital course. The procedure
was performed without any apparent deviations from routine hip
arthroplasty protocol. Exparel was inﬁltrated into the 3 soft tissue
locations according to the protocol. Postoperatively, leg length
measurements were equal.
In the recovery room, he exhibited full strength in his gastroc-
nemius/soleus muscle groups of his left lower extremity, but 0/5
strength in his extensor hallucis longus and tibialis anterior mus-
cles. Sensory exam also revealed numbness in the superﬁcial
peroneal and deep peroneal nerve distributions. At this time hewas
positioned with his left hip in extension and knee in ﬂexion and
underwent serial physical exams. He reported a pain level of 3/10,
which was managed with hydromorphone 25 mg/250 mL PCA in
the recovery room and overnight after transfer to the ﬂoor. The PCA
was discontinued on the morning of POD 1. For the remainder of
her hospital stay, he was continued on an oral pain control regimen
of celecoxib 200 mg daily, pregabalin 50 mg twice daily, oxycodone
CR 10 mg twice daily, and oxycodone IR 10 mg every 4 h as needed
for breakthrough pain.
On POD 1, his motor and sensory exam remained unchanged.
Serial exams showed a slow, but progressive, restoration in func-
tion. The patient was made weight bearing as tolerated with a
rolling walker. By POD 2, the patient was neurologically intact
throughout the left lower extremity except for 4þ/5 strength in
tibialis anterior and 4/5 in extensor hallucis longus muscles.
Sensation to light touch was intact in all distributions. By the
morning of POD 3, he was neurologically intact with 5/5 strength
and intact sensation throughout his left lower extremity. He was
able to meet established physical therapy goals by walking 150 feet
and clearing 4 stairs. At the end of POD 3, he was discharged home.
He received visiting nurse services for wound care and physical
therapy, was instructed to continue WBAT with wheeled walker,
take aspirin 325mg twice daily and towear foot pumps for 18e20 h
daily for venous thromboembolism prophylaxis for 4 weeks, take
amoxicillin 875 mg twice daily for 4 weeks for infection prophy-
laxis, and take oxycodone-acetaminophen 5e325 mg as needed for
pain control. He had no neurological deﬁcits at his 2 week
evaluation.
Discussion
Liposomal bupivacaine (Exparel®) is a novel medication that
can provide long lasting pain relief as part of a multimodal
pain regimen [10,12e16]. In the three THA cases described, the
patients exhibited a transient loss of neurologic function in the
affected extremity lasting between 24 and 72 h. We believe
this occurred as a result of unintended injection of the medi-
cation in close proximity to the sciatic nerve. The three patientcases were performed by two different surgeons at the same
institution. Each of the surgeons followed the injection proto-
col. While all patients had risk factors for experiencing a
neurologic deﬁcitdone had prior spine surgery, one patient
had DDH, and the third had multiple previous hip surger-
iesdnone of the patients had excessive lengthening of the limb
or a preoperative neurologic deﬁcit.
Aggressive injection of themedication around the short external
rotators and pericapsular fat during total hip arthroplasty may
result in unanticipated sciatic nerve anesthesia. These occurrences
do not appear to be reported in the current literature. Surgeons
who use liposomal bupivacaine as part of a multimodal pain
treatment regimen need to be aware of the possibility of inadver-
tent sciatic nerve injection. We recommend that orthopaedic sur-
geons pay special attention during inﬁltration of the medication as
unintended transient postoperative anesthetic-induced deﬁcits
have the potential to be confused with more serious causes of
neurologic deﬁcits. Delaying neurologic work-up or imaging, ankle-
foot orthosis ﬁtting, and operative intervention in the setting of
painless sciatic nerve injury without suspicion of surgical insult,
hematoma, or preoperative susceptibility until liposomal bupiva-
caine effects dissipate at 48e72 h postoperatively seems prudent.
Unlike cases of traumatic injury to the sciatic nerve by retractor or
stretch, the transient anesthetic episodes exhibited in these three
cases were not associated with pain or dysesthesia in the sciatic
nerve sensory distribution. Ultimately, it is our hope that surgeons
be able to identify similar cases of neurologic deﬁcits due to lipo-
somal bupivacaine injections in order to avoid unnecessary,
expensive, and potentially harmful evaluations, treatments, and
re-operations.
Summary
In the three total hip arthroplasty cases described, all patients
exhibited a transient loss of neurologic function in the sciatic nerve
distribution of the operated extremity lasting between 24 and 72 h
during the immediate postoperative period. Due to the nature and
duration of the deﬁcits, it was concluded that they likely occurred
as a result of unintended injection of liposomal bupivicaine
(Exparel®) in close proximity to the sciatic nerve. To the best of our
knowledge, these events have yet to be reported in the current
literature. We recommend orthopaedic surgeons pay special
attention during inﬁltration of the medication at the surgical site to
avoid postoperative neurological deﬁcits.
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